DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

846 initially tolerating antiarrhythmic therapy: A multicenter,
double-blind, crossover study of flecainide and placebo with
transtelephonic monitoring. Flecainide Supraventricular
Tachycardia Study Group. Circulation, 1989, 80:1557–1570.
Anderson JL, Rodier HE, Green LS. Comparative effects of
β-adrenergic blocking drugs on experimental ventricular fibrillation
threshold. Am J Cardiol, 1983, 51:1196–1202.
Balser JR, Nuss HB, Orias DW, et al. Local anesthetics as effectors
of allosteric gating: Lidocaine effects on inactivation-deficient
rat skeletal muscle Na channels. J Clin Invest, 1996,
98:2874–2886.
Bankston JR, Kass RS. Molecular determinants of local anesthetic
action of beta-blocking drugs: Implications for management
of long QT syndrome variant 3. J Mol Cell Cardiol,
2010, 48:246–253.
Bean BP. Two kinds of calcium channels in canine atrial cells.
Differences in kinetics, selectivity, and pharmacology. J Gen
Physiol, 1985, 86:1–30.
Bennett PB, Woosley RL, Hondeghem LM. Competition
between lidocaine and one of its metabolites, glycylxylidide,
for cardiac sodium channels. Circulation, 1988, 78:692–700.
Biaggioni I, Killian TJ, Mosqueda-Garcia R, et al. Adenosine
increases sympathetic nerve traffic in humans. Circulation,
1991, 83:1668–1675.
Brown MJ, Brown DC, Murphy MB. Hypokalemia from β 2
-
receptor stimulation by circulating epinephrine. N Engl J Med,
1983, 309:1414–1419.
Campbell RW. Mexiletine. N Engl J Med, 1987, 316:29–34.
Cardiac Arrhythmia Suppression Trial II Investigators. Effect of
the antiarrhythmic agent moricizine on survival after myocardial
infarction. N Engl J Med, 1992, 327:227–233.
CAST Investigators. Preliminary report: Effect of encainide and
flecainide on mortality in a randomized trial of arrhythmia
suppression after myocardial infarction. N Engl J Med, 1989,
321:406–412.
Clyne CA, Estes NA III, Wang PJ. Moricizine. N Engl J Med,
1992, 327:255–260.
Cohen IS, Robinson RB. Pacemaker currents and automatic
rhythms: Toward a molecular understanding. Handb Exp
Pharmacol, 2006, 171:41–71.
Connolly SJ. Evidence-based analysis of amiodarone efficacy
and safety. Circulation, 1999, 100:2025–2034.
Courtney KR. Progress and prospects for optimum antiarrhythmic
drug design. Cardiovasc Drugs Ther, 1987, 1:117–123.
Crijns HJ, van Gelder IC, Lie KI. Supraventricular tachycardia
mimicking ventricular tachycardia during flecainide treatment.
Am J Cardiol, 1988, 62:1303–1306.
Data JL, Wilkinson GR, Nies AS. Interaction of quinidine with
anticonvulsant drugs. N Engl J Med, 1976, 294:699–702.
DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Annu
Rev Physiol, 1993, 55:455–472.
Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared
with lidocaine for shock-resistant ventricular fibrillation.
N Engl J Med, 2002, 346:884–890.
Dun W, Boyden PA. The Purkinje cell; 2008 style. J Mol Cell
Cardiol, 2008, 45:617–624.
Dusman RE, Stanton MS, Miles WM, et al. Clinical features of
amiodarone-induced pulmonary toxicity. Circulation, 1990,
82:51–59.
Echizen H, Vogelgesang B, Eichelbaum M. Effects of D,
L-verapamil on atrioventricular conduction in relation to its
SECTION III
MODULATION OF CARDIOVASCULAR FUNCTION
stereoselective first-pass metabolism. Clin Pharmacol Ther,
1985, 38:71–76.
Echt DS, Black JN, Barbey JT, et al. Evaluation of antiarrhythmic
drugs on defibrillation energy requirements in dogs:
Sodium channel block and action potential prolongation.
Circulation, 1989, 79:1106–1117.
Follmer CH, Colatsky TJ. Block of delayed rectifier potassium
current, I K
, by flecainide and E-4031 in cat ventricular
myocytes. Circulation, 1990, 82:289–293.
Fozzard HA, Lee PJ, Lipkind GM. Mechanism of local anesthetic
drug action on voltage-gated sodium channels. Curr
Pharm Des, 2005, 11:2671–2686.
Fredj S, Sampson KJ, Lui H, Kass RS. Molecular basis of
ranolazine block of LQT-3 mutant sodium channels: Evidence
for site of action. Br J Pharmacol, 2006, 148:16–24.
Frishman WH, Murthy S, Strom JA. Ultra-short-acting
β-adrenergic blockers. Med Clin North Am, 1988, 72:359–372.
Fromm MF, Kim RB, Stein CM, et al. Inhibition of P-glycoproteinmediated
drug transport: A unifying mechanism to explain the
interaction between digoxin and quinidine. Circulation, 1999,
99:552–557.
Funck-Brentano C, Kroemer HK, Lee JT, Roden DM.
Propafenone. N Engl J Med, 1990, 322:518–525.
Grace AA, Camm J. Quinidine. N Engl J Med, 1998, 338:35–45.
Gross AS, Mikus G, Fischer C, et al. Stereoselective disposition
of flecainide in relation to sparteine/debrisoquine metaboliser
phenotype. Br J Clin Pharmacol, 1989, 28:555–566.
Henthorn RW, Waldo AL, Anderson JL, et al. Flecainide acetate
prevents recurrence of symptomatic paroxysmal supraventricular
tachycardia. The Flecainide Supraventricular Tachycardia
Study Group. Circulation, 1991, 83:119–125.
Herbette LG, Trumbore M, Chester DW, Katz AM. Possible
molecular basis for the pharmacokinetics and pharmacodynamics
of three membrane-active drugs: Propranolol, nimodipine
and amiodarone. J Mol Cell Cardiol, 1988, 20:373–378.
Hilliard FA, Steele DS, Laver D, et al. Flecainide inhibits
arrhythmogenic Ca 2+ waves by open state block of ryanodine
receptor Ca 2+ release channels and reduction of Ca 2+ spark
mass. J Mol Cell Cardiol, 2010, 48:293-301.
Hine LK, Laird N, Hewitt P, Chalmers TC. Meta-analytic evidence
against prophylactic use of lidocaine in acute myocardial
infarction. Arch Intern Med, 1989, 149:2694–2698.
Hohnloser SH, Woosley RL. Sotalol. N Engl J Med, 1994,
331:31–38.
Ikeda N, Singh BN, Davis LD, Hauswirth O. Effects of flecainide
on the electrophysiologic properties of isolated canine
and rabbit myocardial fibers. J Am Coll Cardiol, 1985,
5:303–310.
ISIS-4 Collaborative Group. ISIS-4: A randomised factorial trial
assessing early oral captopril, oral mononitrate, and intravenous
magnesium sulphate in 58,050 patients with suspected
acute myocardial infarction. ISIS-4 (Fourth International
Study of Infarct Survival) Collaborative Group. Lancet, 1995,
345:669–685.
Kessler KM, Kissane B, Cassidy J, et al. Dynamic variability of
binding of antiarrhythmic drugs during the evolution of acute
myocardial infarction. Circulation, 1984, 70:472–478.
Knollmann BC, Roden DM. A genetic framework for improving
arrhythmia therapy. Nature, 2008, 451:929–936.
Kowey PR, Levine JH, Herre JM, et al. Randomized, doubleblind
comparison of intravenous amiodarone and bretylium in